Hypoxic pulmonary vasoconstriction

Clinical relevance (why it matters in anaesthesia)

HPV is an intrinsic pulmonary vascular response that diverts blood away from hypoxic alveoli to better-ventilated regions, improving V/Q matching and arterial oxygenation.
Most important when lung units are heterogeneously ventilated (e.g. one-lung ventilation, lobar collapse, pneumonia, pulmonary oedema).
Anaesthetic drugs and physiological derangements can attenuate HPV → increased shunt fraction → worse PaO2.
Global hypoxia (e.g. high altitude, severe hypoventilation) causes widespread HPV → raised PVR → pulmonary hypertension and RV strain.

High-yield clinical scenarios

One-lung ventilation: HPV reduces perfusion to non-ventilated lung; inhibition of HPV increases shunt and hypoxaemia.
Atelectasis (including after induction): HPV partly compensates; recruitment/PEEP may improve oxygenation by restoring ventilation but excessive PEEP can increase PVR and redistribute flow.
COPD/asthma with regional hypoventilation: HPV helps maintain oxygenation; vasodilators can worsen V/Q mismatch.
ARDS: HPV may be impaired by inflammation/endothelial dysfunction; high airway pressures and vasodilators may worsen oxygenation.

Definition and purpose

HPV is constriction of small pulmonary arteries/arterioles in response to low alveolar oxygen tension, reducing perfusion to poorly ventilated lung regions.
Primary stimulus is low alveolar PO2 (PAO2); mixed venous PO2 (PvO2) also modulates the response.
- PAO2 reflects local ventilation; therefore HPV is a local matching mechanism.
Physiological aim: optimise V/Q matching and reduce shunt; at the expense of increased PVR if widespread.

Site and time course

Occurs predominantly in small muscular pulmonary arteries/arterioles supplying the affected alveolar units (pre-capillary).
Biphasic response to sustained hypoxia.
- Phase 1: rapid onset within seconds to minutes (peaks ~15 min).
- Phase 2: slower, sustained augmentation over ~30–120 min (mechanisms include gene expression, mediator release, vascular remodelling with prolonged hypoxia).

Stimulus–response characteristics

Threshold: HPV becomes significant as PAO2 falls below ~70 mmHg (≈ 9–10 kPa), with increasing response as PAO2 decreases further; maximal around PAO2 ~25–30 mmHg (≈ 3–4 kPa).
Very low PAO2 may reduce HPV (vascular collapse/atelectasis and loss of alveolar tethering can alter local mechanics), but exam answers usually emphasise a plateau at low PAO2.
PvO2: low mixed venous oxygen tension augments HPV; high PvO2 attenuates it (important during high FiO2 and high cardiac output states).

Cellular mechanism (core FRCA explanation)

Hypoxia is sensed by pulmonary arterial smooth muscle cells (PASMC) leading to membrane depolarisation and Ca2+ influx → contraction.
Key steps commonly described:
- Hypoxia inhibits O2-sensitive K+ channels (e.g. Kv) → reduced K+ efflux → depolarisation.
- Depolarisation opens voltage-gated L-type Ca2+ channels → increased intracellular Ca2+.
- Ca2+–calmodulin activates myosin light chain kinase → smooth muscle contraction.
- Rho-kinase pathway increases Ca2+ sensitivity (inhibits myosin light chain phosphatase) contributing to sustained phase.
Endothelium modulates HPV: balance between vasoconstrictors (endothelin-1, thromboxane) and vasodilators (NO, prostacyclin).

Factors that increase HPV (augment response)

Lower PAO2 (regional hypoxia) and lower PvO2.
Acidosis (especially respiratory acidosis) and hypercapnia tend to augment HPV.
Hypothermia may augment HPV (but severe hypothermia has complex haemodynamic effects).
Alpha-adrenergic stimulation can enhance pulmonary vasoconstriction (less consistent for pure HPV but relevant in vivo).

Factors that decrease HPV (inhibit response) — key anaesthetic list

Volatile anaesthetics inhibit HPV in a dose-dependent manner (most evident at >1 MAC).
- Clinical impact depends on context: during one-lung ventilation, inhibition can worsen shunt and PaO2; effects are smaller at ≤1 MAC and with modern practice.
Vasodilators: nitroprusside, nitroglycerin, hydralazine, calcium channel blockers, prostacyclin analogues can inhibit HPV and worsen V/Q mismatch.
Increased pulmonary arterial pressure/flow can blunt HPV (distension recruits vessels and reduces relative constriction effect).
Alkalosis and hypocapnia attenuate HPV.
Inflammation/endothelial dysfunction (e.g. sepsis, ARDS) can impair HPV.
High FiO2 can reduce the stimulus in marginal units (increasing PAO2) and increase PvO2, both tending to reduce HPV-driven redistribution.

Effects of anaesthetic techniques and drugs

IV anaesthetics (propofol, etomidate, ketamine, opioids) have minimal direct inhibition of HPV at clinical doses compared with volatiles.
Volatile agents: all inhibit HPV to some extent; dose-dependent; differences between agents are small clinically at equipotent doses.
Regional anaesthesia: by avoiding volatiles and maintaining spontaneous ventilation in selected cases, may preserve HPV and reduce atelectasis-related shunt (context dependent).
Inhaled pulmonary vasodilators (NO, nebulised prostacyclin): can improve oxygenation in V/Q mismatch by selectively dilating ventilated regions (functional opposite of systemic vasodilators).

HPV and shunt during one-lung ventilation (numbers and concepts)

Without HPV, perfusion to the non-ventilated lung would approximate its share of cardiac output (often ~40–50% depending on position and anatomy), producing a large shunt.
With HPV, blood flow to the non-ventilated lung is reduced (often to ~20–30%), reducing shunt and improving PaO2.
Other determinants of oxygenation during OLV: gravity/positioning (lateral decubitus), surgical manipulation, airway pressures/PEEP/CPAP, cardiac output, FiO2, and lung pathology.

Integration with pulmonary vascular resistance (PVR) and pulmonary hypertension

Regional HPV improves gas exchange; global HPV increases PVR and pulmonary artery pressure.
Chronic hypoxia (e.g. COPD, high altitude) → sustained HPV + vascular remodelling → pulmonary hypertension and RV hypertrophy/failure risk.

Define hypoxic pulmonary vasoconstriction and explain its physiological role.

Aim for a clear definition plus the V/Q matching rationale.

HPV is constriction of pulmonary resistance vessels in response to reduced alveolar PO2 in a lung region.
It diverts blood flow away from poorly ventilated alveoli toward better ventilated units, improving V/Q matching and reducing shunt.
If hypoxia is global, HPV increases PVR and pulmonary artery pressure, potentially stressing the RV.

What is the main stimulus for HPV: PaO2, PAO2, or PvO2? How do these interact?

Examiners want: PAO2 is primary, PvO2 modulates.

Primary stimulus is low alveolar PO2 (PAO2) in the affected lung unit (local control).
Mixed venous PO2 (PvO2) modulates HPV: lower PvO2 augments, higher PvO2 attenuates the response.
Arterial PO2 (PaO2) is a result of gas exchange and does not directly drive local HPV in the same way as PAO2.

Describe the cellular mechanism of HPV in pulmonary arterial smooth muscle.

Give a channel-based explanation plus Ca2+ and endothelium modulation.

Hypoxia inhibits O2-sensitive K+ channels in PASMC → depolarisation.
Depolarisation opens voltage-gated L-type Ca2+ channels → increased intracellular Ca2+ → contraction via MLCK.
Rho-kinase increases Ca2+ sensitivity, contributing to sustained vasoconstriction.
Endothelium-derived mediators modulate: endothelin/thromboxane promote; NO/prostacyclin oppose.

Explain the time course of HPV and its clinical relevance during one-lung ventilation.

Biphasic response and timing relative to OLV onset is commonly examined.

Phase 1: rapid onset within seconds–minutes; peaks around 15 minutes.
Phase 2: slower augmentation over 30–120 minutes, sustaining diversion of blood flow.
During OLV, oxygenation may improve after initial deterioration as HPV develops; inhibition (e.g. high-dose volatiles) can blunt this improvement.

List factors that inhibit HPV and explain how this can worsen oxygenation.

Link inhibition → increased perfusion of hypoxic units → increased shunt.

Volatile anaesthetics (dose-dependent, especially >1 MAC).
Systemic vasodilators: GTN, SNP, hydralazine, calcium channel blockers; prostacyclin.
Alkalosis and hypocapnia.
Sepsis/ARDS (endothelial dysfunction), and high pulmonary blood flow/pressure (blunting effect).
Mechanism of worsened oxygenation: more blood continues to perfuse poorly ventilated/non-ventilated units → increased shunt fraction → reduced PaO2.

How do hypercapnia and acidosis affect HPV? What about hypocapnia?

Hypercapnia and acidosis tend to augment HPV (and increase PVR).
Hypocapnia and alkalosis attenuate HPV.
Clinically, profound hypocapnia during OLV may worsen oxygenation by reducing HPV-mediated diversion of blood flow.

Compare the effects of volatile and intravenous anaesthetics on HPV.

Volatile agents inhibit HPV in a dose-dependent manner; effect becomes more clinically relevant at higher MAC and in situations relying on HPV (e.g. OLV).
IV agents (propofol, etomidate, ketamine, opioids) have minimal direct inhibition of HPV at clinical doses.
Overall oxygenation depends on multiple factors (atelectasis, airway pressures, CO), so drug choice is only one component.

During one-lung ventilation, why might inhaled nitric oxide improve oxygenation whereas intravenous vasodilators may worsen it?

This tests selective vs non-selective pulmonary vasodilation and V/Q effects.

Inhaled NO reaches ventilated alveoli only → selectively dilates vessels in ventilated regions → increases perfusion to well-ventilated units and improves V/Q matching.
IV vasodilators dilate pulmonary vessels in both ventilated and non-ventilated regions → can increase perfusion of hypoxic/non-ventilated units → increased shunt and worse oxygenation.

Explain how HPV relates to pulmonary hypertension in chronic lung disease and at high altitude.

Chronic hypoxia causes sustained HPV plus vascular remodelling (medial hypertrophy, intimal changes) → increased PVR and pulmonary artery pressure.
This can lead to RV hypertrophy and eventual RV failure (cor pulmonale).
At high altitude, global hypoxia can precipitate pulmonary hypertension; uneven HPV is implicated in high-altitude pulmonary oedema (HAPE).

A previous FRCA-style written question: 'Describe the factors affecting hypoxic pulmonary vasoconstriction and the implications for anaesthesia.' Provide a structured answer.

Use headings: stimulus, mechanism, augment/inhibit, clinical implications.

Stimulus: low PAO2 (primary) with modulation by PvO2; response is local and biphasic over time.
Mechanism: PASMC K+ channel inhibition → depolarisation → L-type Ca2+ influx; endothelial mediators (ET-1/TxA2 vs NO/PGI2) modulate; Rho-kinase contributes to sustained phase.
Augment: hypoxia severity, low PvO2, hypercapnia, acidosis (and sometimes hypothermia).
Inhibit: volatile anaesthetics (dose-dependent), systemic vasodilators, alkalosis/hypocapnia, high flow/pressure, sepsis/ARDS/endothelial dysfunction.
Implications: during OLV and regional lung disease, preserved HPV improves oxygenation; inhibition increases shunt and hypoxaemia; in global hypoxia HPV increases PVR and RV afterload.

A previous FRCA-style viva prompt: 'Your patient becomes hypoxic during one-lung ventilation. Talk about HPV and how your anaesthetic might be contributing.' What points would you cover?

HPV should reduce perfusion to the non-ventilated lung; if HPV is inhibited, shunt increases and PaO2 falls.
Check volatile concentration: higher MAC inhibits HPV; consider reducing volatile dose and supplementing with IV agents/opioid.
Avoid unnecessary systemic vasodilators that may worsen V/Q mismatch.
Consider ventilation strategy effects: excessive airway pressures/PEEP may increase PVR and alter perfusion distribution; ensure optimal positioning and lung isolation; consider CPAP to non-dependent lung or PEEP to dependent lung as appropriate.
Remember other determinants: cardiac output (high CO can worsen shunt fraction effect), Hb, FiO2, atelectasis, secretions, surgical compression.